1083P KEYMAKER 02B: A randomized trial of pembrolizumab (pembro) alone or with investigational agents as first-line treatment for advanced melanoma
Reinhard Dummer(University Hospital of Zurich), Georgina V. Long(The University of Sydney), Joel E. Cohen(Rockefeller University), C. Krepler(Merck & Co., Inc., Rahway, NJ, USA (United States)), David C. Portnoy(Campbell Clinic), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Graham Cohen(Life Groenkloof Hospital), C. Gaudy Marqueste(Hôpital de la Timone), Jacopo Pigozzo(Istituto Oncologico Veneto), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Gil Bar‐Sela(Emek Medical Center), Richa Lal(MSD (UK) Limited (United Kingdom)), Antoni Ribas(University of California, Los Angeles), R. Dokhan(Rambam Health Care Campus), Anna Maria Di Giacomo(University of Siena), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Roni Shapira(Sheba Medical Center), Carmen Belli(European Institute of Oncology)
Cited by 3
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k